Evonik, a global CMO leader for API and advanced intermediates, announced the completion of a €36 million expansion of its contract manufacturing capabilities in the U.S. and Europe.
A series of advanced technologies, including high-potency API (HPAPI), fermentation, mPEGs and continuous processing, have been introduced or enhanced at multiple Evonik production sites over the last year.
At its facility in Hanau, Germany, Evonik has recently commissioned a new modular cGMP continuous processing plant, a pilot plant for the custom synthesis of highly pure PEGs and mPEGs for pharmaceutical applications, as well as a cGMP suite for the small-scale production of HPAPI and ultra-HPAPI.
At its facilities in Tippecanoe, Indiana, U.S. and Hanau, Germany, Evonik has increased its asset footprint and added additional capacities to support the small, medium or large scale production of HPAPI. In addition to being the world’s largest HPAPI manufacturer, Evonik is now able to run several HPAPI projects in parallel down to an exposure level (OEL) of 5ng/m³.
At its facility in Slovakia, Evonik has recently invested in a new, flexible pilot plant for downstream processing. It is the sixth plant in a worldwide network to support microbial fermentation projects from strain development through to commercial manufacturing.
Evonik Industries AG is an industrial corporation headquartered in Essen, North Rhine-Westphalia (Germany), the largest specialty chemicals company in the world, owned by RAG Foundation.